immuno-oncology

News

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

News

EMA starts review of Novartis' latecomer PD-1 drug tislelizu...

The EU regulator has started a review of Novartis' PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the dr

News

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

Immunocore now has approval on both sides of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the Europe

News

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions

News

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi

News

AstraZeneca's Imfinzi fails in cervical cancer bid

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for wo

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

EMA starts review of Novartis' latecomer PD-1 drug tislelizu...

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

CHMP backs J&J's myeloma CAR-T therapy Carvykti

AstraZeneca's Imfinzi fails in cervical cancer bid

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks